Efficacy and safety of low dose, weight-based subcutaneous enoxaparin protocol in recurrent arteriovenous access thrombosis
The Journal of Vascular Access · 2024
DOI: 10.1177/11297298231194102 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift The Journal of Vascular Access, 2024. Verfasst von Chye Chung Gan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Singapore General Hospital, Singapore. Hauptthemen laut MEDLINE: Enoxaparin, Vascular Patency, Recurrence, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
This study aims to evaluate the safety and efficacy of a short-term, low dose, weight-based subcutaneous enoxaparin protocol (SEP) in maintaining the patency of arteriovenous (AV) access with recurrent thrombosis.
Methods
Prospective follow-up of 25 patients who presented to a tertiary institution with recurrent AV access thrombosis and treated with anticoagulation according to SEP following successful thrombectomy. Patency and safety outcomes of SEP were studied.
Results
The participants were 66.4 ± 10.2 years old and predominantly male (60%) and of Chinese ethnicity (72%). The AV accesses had a median age of 1.4 (0.6, 5.6) years with 60% being non-autogenous arteriovenous access while 40% were autogenous arteriovenous access. Thrombolytic agents (urokinase (72%) or alteplase (28%)) were used in all procedures while adjunct thrombectomy device was used in only four procedures. The mean dose of enoxaparin was 36.0 ± 8.2 mg or 0.64 ± 0.1 mg/kg/day for a mean duration 30.0 days (Interquartile range: 27.5, 31.0). One patient developed minor bleeding episode. Kaplan-Meier analysis demonstrated that the mean thrombosis-free survival pre- versus post-SEP adoption was 27.3 (95% CI 17.9–36.7) versus 183.5 (95% CI 100.1–266.9) days ( p < 0.001). After adjusting for the type of thrombolytic agent, use of adjunct thrombectomy device, cutting balloon, drug-coated balloon, and stent graft, SEP remained a significant factor associated with longer thrombosis-free patency (HR 0.166: 95% CI 0.070–0.392, p < 0.001).
Discussion
SEP appears to be a feasible and safe thromboprophylaxis method to improve thrombosis-free patency for AV access with recurrent thrombosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Renal Medicine, Singapore General Hospital, Singapore.
- Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia.
- Duke NUS Graduate Medical School, Singapore.
- Department of Hematology, Singapore General Hospital, Singapore.
- Department of Vascular and Interventional Radiology, Singapore General Hospital, Singapore.
- Department of Vascular Surgery, Singapore General Hospital, Singapore.
ORCID-Profile: Chye Chung Gan, Ru Yu Tan, Ren Kwang Alvin Tng, Chieh Suai Tan
Zitieren
APA
Gan, C. C., Tan, R. Y., Cheong, M. A., Pang, S. C., Tng, R. K. A., Tan, C. W., Lee, L. H., Ng, H. J., Tay, K. H., Chong, T. T., & Tan, C. S. (2024). Efficacy and safety of low dose, weight-based subcutaneous enoxaparin protocol in recurrent arteriovenous access thrombosis. The Journal of Vascular Access. https://doi.org/10.1177/11297298231194102
Vancouver
Gan CC, Tan RY, Cheong MA, Pang SC, Tng RKA, Tan CW, et al. Efficacy and safety of low dose, weight-based subcutaneous enoxaparin protocol in recurrent arteriovenous access thrombosis. The Journal of Vascular Access. 2024. doi:10.1177/11297298231194102
BibTeX
@article{Gan2024,
author = {Gan, Chye Chung and Tan, Ru Yu and Cheong, May Anne and Pang, Suh Chien and Tng, Ren Kwang Alvin and Tan, Chee Wooi and Lee, Lai Heng and Ng, Heng Joo and Tay, Kiang Hiong and Chong, Tze Tec and Tan, Chieh Suai},
title = {Efficacy and safety of low dose, weight-based subcutaneous enoxaparin protocol in recurrent arteriovenous access thrombosis},
journal = {The Journal of Vascular Access},
year = {2024},
doi = {10.1177/11297298231194102}
}
EUVIMED